The US FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice for active pharmaceutical ingredients.

On Jan. 15, 2025, a warning letter was sent to Sanofi stating that FDA inspectors found irregularities with the facility's bioreactor, the vessel used to grow organisms and cells. According to the ...

Sanofi Ventures and EQT Life Sciences co-led ... Atalanta plans to file two Investigational New Drug Applications in 2025 and soon thereafter enter the clinic in KCNT1-related epilepsy and ...

As you can see from the chart above the percentage of shares that are sold short for Sanofi has grown since its last report. This does not mean that the stock is going to fall in the near-term but ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As part of its enforcement activities, the Food and Drug Administration (FDA) sends warning letters to entities under its jurisdiction. Some letters are not posted for public view until weeks or ...

Federal regulators have warned a Waco company that its human amniotic products are “unlicensed” and “unapproved,” and that ...

Opella, Sanofi's (NASDAQ:SNY) Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned actual use trial (AUT) to support the ...